An Effective Hormonal Therapy for a Patient with Estrogen Receptor 1 (ESR1)-Amplified Metastatic Ovarian Cancer: A Case Report
DOI: https://doi.org/10.2147/OTT.S363856
IF: 4
2022-06-09
OncoTargets and Therapy
Abstract:Yue Wang, 1, &ast Shuang Tan, 2, &ast Evenki Pan, 3 Yutong Ma, 3 Xue Wu, 3 Zhe Yu, 1 Kui Jiang 1 1 Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China; 2 Department of Gynecology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China; 3 Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kui Jiang; Zhe Yu, Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China, Tel +8617709873696 ; +8618641103913, Email ; Hormonal therapy is an important treatment option for estrogen receptor (ER)-positive patients with advanced ovarian cancer. Although ER overexpression has been previously used as an indicator for hormonal therapy, the clinical outcomes of advanced ovarian cancer patients receiving hormonal therapy remain unsatisfactory. Additional biomarkers for screening patients are needed to improve its efficacy. In this study, we reported a metastatic ovarian cancer case with estrogen receptor 1 ( ESR1 ) gene amplification and protein overexpression, which showed sustained partial response to hormonal therapy, including letrozole and tamoxifen, and displayed an overall survival of 47 months. The response to the therapy was evaluated by imageological examinations, cancer antigen-125 (CA-125) tests, and circulating tumor DNA (ctDNA) sequencing using capture-based hybrid next-generation sequencing. Our clinical data suggested that ESR1 amplification might be a potential predictor of response to hormonal therapy in ovarian cancer. The combination of tumor detection techniques including imaging, CA-125 and ctDNA would enable confirmation of tumor response with high confidence. Keywords: ESR1 amplification, ovarian cancer, hormonal therapy, letrozole, tamoxifen, circulating tumor DNA Ovarian cancer is the second leading cause of gynecologic cancer death. 1 It accounts for 3.6% and 4.4% of female new cancer cases and deaths per year worldwide. 2 In China, its incidence and mortality among all female cancer cases are 2.9% and 2.2%, slightly lower than the global level. 3 At present, tumor cytoreductive surgery combined with platinum-based chemotherapy is the primary treatment for advanced ovarian cancer. 4 Although the surgery in combination with chemotherapy is effective for most patients, its efficacy for ovarian cancer is not satisfactory and the recurrent rate of ovarian cancer remains high. Hormonal therapy is one of the treatment options for patients with estrogen receptor (ER)-positive advanced ovarian cancer. Studies have shown that the objective response rate and disease stability duration of high-grade serous ovarian cancer patients receiving hormonal therapy were ~15% and 9.6 months, respectively. 5 The insufficient efficacy of hormonal therapy in ER-positive patient cohort limits its clinical application in advanced ovarian cancer and the identification of additional biomarkers for rational patient selection to improve its efficacy is paramount. There are two subtypes of ER proteins, ERα and ERβ, which are encoded by estrogen receptor 1 ( ESR1 ) and ESR2 genes, respectively. It has been reported that 25%–86% of ovarian cancers have ER expression. 6 The success of hormonal therapy in breast cancer and the high frequency of ER expression in ovarian cancer have spurred great effort in evaluating hormonal therapy's efficacy in ovarian cancer. Albeit its low frequency in ovarian cancer, ERS1 gene amplification has been shown 100% associated with ER expression in ovarian cancer, 6 indicating it is one of the mechanisms for upregulating ER expression. To our knowledge, we reported the first case of ESR1 -amplified metastatic ovarian cancer that showed a durable response to both tamoxifen- and letrozole-based hormonal therapy. Our case report encouraged further exploration of hormonal therapy biomarkers for precision medicine in ovarian cancer. In March 2016, a 78-year-old female patient diagnosed with stage IIIC ovarian cancer underwent cytoreductive surgery. Tumor nodules were found in the right ovary, right fallopian tube, left ovary, appendix, omentum, and umbilicus. Postoperative pathology of tumor samples from the ovary revealed high-grade serous adenocarcinoma (Figure 1A). Cancer antigen 125 (CA-125) decreased from 441.82 U/mL to 71.01 U/mL after cytoreductive surgery (Figure 1B). Subsequently, she was tre -Abstract Truncated-
oncology,biotechnology & applied microbiology